凯盛新材(301069) - 2024 Q1 - 季度财报

Financial Performance - Revenue for Q1 2024 was CNY 239,937,179.44, a decrease of 3.26% compared to CNY 248,028,189.67 in the same period last year[5] - Net profit attributable to shareholders was CNY 25,698,384.59, down 49.29% from CNY 50,672,203.78 year-on-year[5] - Net profit after deducting non-recurring gains and losses was CNY 21,679,169.31, a decrease of 56.87% compared to CNY 50,266,825.50 in the previous year[5] - Total operating revenue for Q1 2024 was CNY 239,937,179.44, a decrease of 3.4% compared to CNY 248,028,189.67 in Q1 2023[25] - Net profit for Q1 2024 was CNY 25,613,364.76, down 49.5% from CNY 50,609,357.55 in Q1 2023[26] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.0611, compared to CNY 0.1205 in the same period last year[27] Cash Flow and Liquidity - Operating cash flow net amount increased by 125.57% to CNY 13,726,887.23 from a negative CNY 53,679,767.28 in the same period last year[5] - Net cash flow from operating activities increased by CNY 67,406,700, mainly due to increased cash received from sales of goods and services[14] - The company’s cash and cash equivalents decreased from 849,328,531.65 CNY to 449,137,602.91 CNY, a decline of approximately 47%[21] - The total cash and cash equivalents at the end of the period is ¥415,726,948.25, down from ¥820,568,630.71 at the beginning of the period[30] - Cash received from sales of goods and services reached ¥181,110,877.58, up from ¥93,920,685.71 in the previous period, reflecting a growth of approximately 93%[29] - The total cash outflow from operating activities was ¥172,189,186.28, compared to ¥150,013,047.51 in the previous period, representing an increase of about 15%[29] Assets and Liabilities - Total assets at the end of the period were CNY 2,452,035,545.57, a decrease of 1.24% from CNY 2,482,942,697.11 at the end of the previous year[5] - Total liabilities decreased to CNY 757,488,346.84 from CNY 814,013,531.73 in the previous year[24] - The total current assets amount to 1,419,355,660.61 CNY, down from 1,449,868,417.10 CNY, indicating a decrease of about 2.1%[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,330[17] - The largest shareholder, Huabang Life Health Co., Ltd., holds 44.51% of the shares, totaling 187,216,000 shares[17] - The company has no preferred shareholders or changes in restricted shares during the reporting period[19] - The top ten shareholders do not participate in margin financing or securities lending activities[18] - The total number of restricted shares at the end of the period is 280,200,000, with no new restrictions added[20] Investment and Expenses - Financial expenses increased by 3422.64% to CNY 5,600,000 due to convertible bond interest expenses[10] - Investment income increased by 326.50% to CNY 2,600,000, attributed to the increase in the scale of financial products[11] - The company reported a significant increase in other income by 240.58% to CNY 1,000,000, primarily due to deferred income amortization[11] - The company reported a significant increase in research and development expenses, totaling CNY 10,486,648.77, compared to CNY 14,307,857.49 in Q1 2023[25] Cash Flow from Investments - Cash inflow from investment activities totaled ¥805,259,504.73, compared to ¥175,322,440.47 in the previous period, indicating a substantial increase[30] - The net cash flow from investment activities is -¥414,274,828.75, worsening from -¥16,254,776.14 in the previous period[30] - The cash paid for purchasing goods and services was ¥120,195,474.81, an increase from ¥94,596,865.66 in the previous period, indicating a rise of approximately 27%[29] - The company reported a cash inflow of ¥800,684,537.59 from investment recoveries, a significant increase from ¥173,884,220.41 in the previous period[30] - The cash outflow for the acquisition of fixed assets and other long-term assets was ¥2,558,233.48, down from ¥9,867,216.61 in the previous period, showing a decrease of about 74%[30]